

Organized by



National and Kapodistrian
University of Athens
School of Medicine
Department of Pathophysiology



Institute of Autoimmune
Systemic and Neurological
Disorders

8th Summer School of Immunology

www.immunologysummerschool2021.gr

May **24-27**
2021




Virtual

Final Program



ALL TIMES IN
CET
CENTRAL EUROPEAN TIME



Παρακαλούμε επικοινωνήστε με την εταιρεία για επιβεβαίωση πλήρως ενημερωμένων δεδομένων, για οποιαδήποτε πληροφορία ή/και αναφορά Ανεπιθύμητων Ενεργειών στο τηλέφωνο 210 6882100.

Πριν τη συνταγογράφηση συμβουλευτείτε την Περιλήψη των Χαρακτηριστικών του Προϊόντος η οποία είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

PM-GR-BEL-ADVT-190001 ΙΣΧΥΣ 11/2019-11/2021



Benlysta (belimumab)

200 mg/mL

Κάθε 1 ml προγεμισμένης συσκευής τύπου πένας περιέχει 200 mg μπελιμουμάμπης

GlaxoSmithKline
Λ. Κηφισίας 266, 152 32 Αθήνα, Τηλ: 2106882100
www.glaxosmithkline.gr



© 2019 Όμιλος εταιρειών GSK ή δικαιούχος του Ομίλου GSK. Το εμπορικό σήμα ανήκει ή έχει παραχωρηθεί στον Όμιλο Εταιρειών GSK.

Για ενήλικες ασθενείς μέτριας έως σοβαρής ενεργού ρευματοειδούς αρθρίτιδας

ΣΤΟΧΕΥΣΤΕ ΠΕΡΑ ΑΠΟ ΤΑ ΚΑΘΙΕΡΩΜΕΝΑ

olumiant.
(baricitinib) tablets

Για τη θεραπεία ασθενών με ανεπαρκή ανταπόκριση
ή δυσανεξία σε συμβατικά DMARDs¹

Το Olumiant είναι εκλεκτικός και αναστρέψιμος αναστολέας JAK1 και JAK2 για άπαξ ημερησίως χορήγηση, κλινικά δοκιμασμένο σε **>3.770** ασθενείς, εγκεκριμένο σε **>65** χώρες και έχει χορηγηθεί σε **>200.000** ασθενείς.^{2,3}

Κύρια χαρακτηριστικά του Olumiant^{4,5}



Το Olumiant είναι ο **πρώτος αναστολέας JAK** που έδειξε **ανωτερότητα έναντι του adalimumab** στο ACR20 και τη μέση μεταβολή του DAS28, στη 12^η εβδομάδα.^{4,5}



Ταχεία και παρατεταμένη ανταπόκριση: έναρξη δράσης **ήδη από την 1^η εβδομάδα** έναντι του placebo, που διατηρείται για 52 εβδομάδες παρακολούθησης.^{2,3}



Το Olumiant μπορεί να χορηγηθεί ως **μονοθεραπεία ή σε συνδυασμό με MTX¹**



Στατιστικά σημαντικές βελτιώσεις σε **πολλαπλές αναφερθείσες από τους ασθενείς εκβάσεις**, περιλαμβανομένου του **πόνου**, σε σύγκριση με το adalimumab.^{4,6}



Δεδομένα μακροχρόνιας έκθεσης στο Olumiant **έως 8,4 έτη.²**

Η Περιλήψη των Χαρακτηριστικών του Προϊόντος είναι στη διάθεσή σας. Αναζητήστε την από εκπρόσωπο της εταιρείας ή στον παρακάτω υπερσύνδεσμο https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_el.pdf



1. Περιλήψη χαρακτηριστικών προϊόντος Olumiant 2. Genovese MC et al. Poster presented at EULAR Annual meeting 2020. FRI0123. 3. Eli Lilly and Company. Data on file. 4. Taylor PC et al. N Engl J Med 2017;376:652–62. 5. Taylor PC et al. N Engl J Med 2017;376:652–62 (Supplementary appendix). 6. Keystone EC, et al. Ann Rheum Dis 2017;76(11):1853–1861.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και **Αναφέρετε:**
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

Olu_Adv_FullMessage_4.2021

Συνδεθείτε με τη ΦΑΡΜΑΣΕΡΒ ΛΙΛΛΥ στα κοινωνικά δίκτυα



ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε.

15^ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας, 14564 Κηφισιά, **ΤΗΛ.:** 210 6294600, **FAX.:** 2106294610
Για παραγγελίες: ΤΗΛ.: 210 6294629, **e-mail:** orders@lilly.gr, www.lilly.gr



Organized by



Department of Pathophysiology
School of Medicine
National and Kapodistrian University of Athens - Greece
Mikras Asias 75
Athens - 11527
Greece



**Institute of Autoimmune Systemic
and Neurological Disorders,
IASYNN**
Iassiou 8
Athens – 11521
Greece

Summer School Professional Organizer



29 Kosta Varnali St.
Athens – 15233
Greece
T. +30 210 6833600 (call center) | F. +30 210 6847700
E. congress@convin.gr | W. www.convin.gr



Dear students, colleagues and friends,

On behalf of the Organizing Committee, I would like to welcome you to the **8th Summer School of Immunology**, which will be held **virtually** from **24th to 27th May 2021**. Despite our best intentions, the state of the pandemic does not permit us to meet in person this year. Nevertheless, we aspire to an equally interactive and stimulating meeting for all our students, post-docs and Faculty.

This year we will focus on the “Molecular immunology of SARS-CoV2 infection: Pathophysiology, clinical and therapeutic consequences”. The Organizing Committee has prepared a first-rate scientific program with outstanding speakers from leading Universities and Research Institutes around the globe. As in the previous years, our goal is the exchange of knowledge between students, postdocs and Faculty in an informal, alas virtual, atmosphere, and the forging of new research ideas through meaningful interactions.

Our aims will be accomplished through teaching and research lectures, short student presentations and vibrant poster sessions. We are confident that our 8th Summer School of Immunology will be a success and will build long-lasting relationships between established and forthcoming leaders in Immunology.

Professor Athanasios Tzioufas

Department of Pathophysiology, Medical School
National and Kapodistrian University of Athens

Molecular immunology of SARS-CoV2 infection: Pathophysiology, clinical and therapeutic consequences'

Opening Session



Moderators: **Athanasios G. Tzioufas, Evangelos Andreakos**

15.15 – 15.30

Welcoming Address

Athanasios G. Tzioufas, Evangelos Andreakos

15.30 – 16.15

Epidemiology of COVID-19 and response measures to the pandemic

Sotirios Tsiodras

16.15 – 17.00

SARS-CoV2 genome diversity and the UK variant

David Robertson

17.00 – 18.00

Keynote Lecture



Genetic and immunological causes of life-threatening COVID-19

Jean-Laurent Casanova



Immunity to COVID-19 I

Moderator: **Evangelos Andreakos**

09.00 – 09.45 Anti-IL-1 and other biological therapies
Evangelos Giamarelos

09.45 – 10.30 Interferons and epithelial barrier integrity
Andreas Wack

10.45 – 11.15

Break



Immunity to COVID-19 II

Moderator: **Marcus Buggert**

11.15 – 12.00 Type I and III interferons in antiviral immunity to SARS-CoV2 and other viruses
Evangelos Andreakos

12.00 – 12.45 The known and unknowns of T cell immunity to COVID-19
Marcus Buggert

12.45 – 15.00

Break



15.00 – 16.15

Poster Presentations



Immunity to COVID-19 III

Moderator: **Ludmila Prokunina-Olsson**

16.30 – 17.15 Metabolic responses and how they influence outcomes of infectious disease
Catharine Bosio

17.15 – 18.00 Innate lymphoid cells in mucosal Immunity
Marco Colonna

18.00 – 18.45 Genetics of COVID-19
Ludmila Prokunina-Olsson

COVID-19 and long-term consequences I



Moderator: **Panagiotis Vlahoyiannopoulos**

09.00 – 09.45 Immune responses to SARS-CoV-2 and vaccines
Panagiotis Vlahoyiannopoulos

09.45 – 10.20 Cell senescence in COVID-19
Vassilis Gorgoulis

10.20 – 10.45 LongCOVID: Manifestations and clinical consequences
Nikoletta Rovina

10.45 – 11.00

Break



COVID-19 and long-term consequences II



Moderator: **Florent Ginhoux**

11.00 – 11.45 High dimensional analysis of myeloid subsets in COVID-19
Florent Ginhoux

11.45 – 12.30 Single cell approaches to SARS-CoV2 infection
Vassili Soumelis

12.30 – 13.15 Viruses, SARS-COV2 and chronic respiratory diseases
Sebastian Johnston

13.15 – 16.15

Break



COVID-19 and long-term consequences II



Moderator: **George Pavlakis**

16.30 – 17.15 The complosome in COVID-19 pathology
Claudia Kemper

17.15 – 18.00 Systems Biology approaches to vaccines
Bali Pulendran

18.00 – 18.45 How do COVID-19 vaccines work
George Pavlakis



Therapeutic approaches to COVID-19 I

Moderator: **Anastasia Koutsoukou, Harris Alexopoulos**

09.00 – 09.45 COVID-19 therapeutics and management in the ICU
Anastasia Kotanidou

09.45 – 10.30 Immunothrombosis in COVID-19
Panagiotis Skendros

10.30 – 11.15

Break



Therapeutic approaches to COVID-19 II

Moderator: **Peter Katsikis, Michail Lionakis**

11.15 – 12.00 Innate immunity training, vaccines and COVID-19
Mihai Netea

12.00 – 12.45 Applying machine learning to identify immune phenotypes that predict the clinical course of acute COVID-19
Peter Katsikis

12.45 – 13.30 Immune dysregulation in COVID-19 and its targeting with BTK inhibition
Michail Lionakis

13.30 – 14.15 The impact of immune compromise onto adaptive immune responses to SARS-CoV-2
Luigi D. Notarangelo

The Organizing Committee gives a warm welcome to all the companies that contributed with their active involvement to the success of the
8th Summer School of Immunology

MAJOR SPONSOR



SPONSORS



- Alexopoulos Harris** | DPHIL, RESEARCH FELLOW, DEPARTMENT OF PATHOPHYSIOLOGY MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Andreakos Evangelos** | PHD, INVESTIGATOR - PROFESSOR LEVEL CENTER OF TRANSLATIONAL, EXPERIMENTAL SURGERY AND CLINICAL RESEARCH, BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS
- Bosio Catharine (Katy)** | CHIEF, IMMUNITY TO PULMONARY PATHOGENS SECTION, NATIONAL INSTITUTES OF HEALTH, USA
- Buggert Marcus** | MSC, PHD, ASSISTANT PROFESSOR, CENTER FOR INFECTIOUS MEDICINE (CIM), DEPR. OF MEDICINE HUDDINGE, KAROLINSKA INSTITUTET
- Casanova Jean-Laurent** | MD, PHD, LEVY FAMILY PROFESSOR, THE ROCKEFELLER UNIVERSITY, USA / INVESTIGATOR, HOWARD HUGHES MEDICAL INSTITUTE / HEAD, ST. GILES LABORATORY OF HUMAN GENETICS OF INFECTIOUS DISEASES / SENIOR ATTENDING PHYSICIAN, THE ROCKEFELLER UNIVERSITY HOSPITAL / VISITING PROFESSOR, NECKER HOSPITAL AND SCHOOL OF MEDICINE, UNIVERSITY PARIS DESCARTES
- Colonna Marco** | M.D. ROBERT ROCK BELLIVEAU PROFESSOR OF PATHOLOGY AND IMMUNOLOGY UNIVERSITY OF WASHINGTON
- Giamarellos-Bourboulis Evangelos J.** | MD, PHD, FISAC, PROFESSOR OF INTERNAL MEDICINE, DIRECTOR: MASTER (MSC) PROGRAM OF INFECTIOUS DISEASES, 4TH DEPARTMENT OF INTERNAL MEDICINE, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, MEDICAL SCHOOL, GREECE
- Ginhoux Florent** | PHD, PRINCIPAL INVESTIGATOR, SINGAPORE IMMUNOLOGY NETWORK
- Gorgoulis Vassilis** | PROFESSOR HISTOLOGY-EMBRYOLOGY, MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Johnston Sebastian** | PROFESSOR OF RESPIRATORY MEDICINE & ALLERGY HEAD, AIRWAY DISEASE, NATIONAL HEART AND LUNG INSTITUTE, IMPERIAL COLLEGE, LONDON, UK
- Katsikis Peter** | PROFESSOR AND HEAD, DEPARTMENT OF IMMUNOLOGY, ERASMUS MC, UNIVERSITY MEDICAL CENTER ROTTERDAM, NETHERLANDS
- Kemper Claudia** | SENIOR INVESTIGATOR, IMMUNOLOGY CENTER, CHIEF, COMPLEMENT AND INFLAMMATION RESEARCH SECTION, USA
- Kotaniidou Anastasia** | PROFESSOR, MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Koutsoukou Antonia** | PROFESSOR AND DIRECTOR, 1ST DEPARTMENT OF RESPIRATORY MEDICINE, "SOTIRIA" GENERAL HOSPITAL OF CHEST DISEASES, MEDICAL SCHOOL OF ATHENS, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Lionakis Michail** | DEPUTY CHIEF, LABORATORY OF CLINICAL IMMUNOLOGY & MICROBIOLOGY (LCIM), CHIEF, FUNGAL PATHOGENESIS SECTION, LCIM, NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID), NIH, USA
- Netea Mihai** | PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE (463), RADBOD UNIVERSITY MEDICAL CENTER, THE NETHERLANDS
- Notarangelo Luigi D.** | LABORATORY OF CLINICAL IMMUNOLOGY AND MICROBIOLOGY, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, USA
- Pavlakis George** | CHIEF, HUMAN RETROVIRUS SECTION, VACCINE BRANCH, CENTER FOR CANCER RESEARCH, NATIONAL CANCER INSTITUTE, USA
- Prokunina-Olsson Ludmila** | CHIEF AND SENIOR INVESTIGATOR, LABORATORY OF TRANSLATIONAL GENOMICS, DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS, NATIONAL CANCER INSTITUTE, NATIONAL INSTITUTES OF HEALTH, USA
- Pulendran Bali** | VIOLETTA L. HORTON PROFESSOR AND PROFESSOR OF MICROBIOLOGY AND IMMUNOLOGY, STANFORD, USA
- Robertson David** | HEAD OF VIRAL GENOMICS AND BIOINFORMATICS (CENTRE FOR VIRUS RESEARCH), UNIVERSITY OF GLASGOW, UK
- Rovina Nikoletta** | PROFESSOR, MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Skendros Panagiotis** | MD, PHD, ASSOCIATE PROFESSOR OF INTERNAL MEDICINE, FIRST DEPARTMENT OF INTERNAL MEDICINE & LABORATORY OF MOLECULAR HEMATOLOGY, MEDICAL SCHOOL, DEMOCRITUS UNIVERSITY OF THRACE, GREECE
- Soumelis Vassili** | MD, PHD, PROFESSOR, IMMUNOLOGY, UNIVERSITÉ DE PARIS, SENIOR PHYSICIAN, ST LOUIS HOSPITAL, DIRECTOR, INSERM U976
- Tsiodras Sotirios** | PROFESSOR OF MEDICINE AND INFECTIOUS DISEASES AT THE NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS MEDICAL SCHOOL, GREECE
- Tzioufas Athanasios** | MD, PHD, PROFESSOR-DIRECTOR, DEPARTMENT OF PATHOPHYSIOLOGY, MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Vlachoyiannopoulos Panagiotis** | PROFESSOR, DEPARTMENT OF PATHOPHYSIOLOGY, MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE
- Wack Andreas** | SENIOR GROUP LEADER, IMMUNOREGULATION LAB, THE FRANCIS CRICK INSTITUTE, UK



XELJANZ[®]
[tofacitinib citrate]
5 mg tablets

Για πλήρεις συνταγογραφικές πληροφορίες συμβουλευτείτε την Περιλήψη Χαρακτηριστικών του Προϊόντος, όπως έχει εγκριθεί από τις αρμόδιες αρχές.



Pfizer Ελλάς Α.Ε
Λεωφ. Μεσογείων 243, 154 51 Ν. Ψυχικό,
Αρ.Γ.Ε.ΜΗ. 000242901000
Τηλ. 210 6785800
Pfizer Ελλάς ΑΕ Cyprus Branch
Λεωφόρος Αθαλάσσης 26, 2018 Λευκωσία, Κύπρος,
Τηλ: 22817690.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

PP-XEL-GRC-0048-SEP19